- Home
- ALX vs COLL Comparison
ALX vs COLL Comparison
Compare ALX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- COLL
- Stock Information
- Founded
- ALX 1928
- COLL 2002
- Country
- ALX United States
- COLL United States
- Employees
- ALX N/A
- COLL N/A
- Industry
- ALX Real Estate Investment Trusts
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- COLL Health Care
- Exchange
- ALX Nasdaq
- COLL Nasdaq
- Market Cap
- ALX 1.2B
- COLL 958.8M
- IPO Year
- ALX N/A
- COLL 2015
- Fundamental
- Price
- ALX $242.64
- COLL $31.60
- Analyst Decision
- ALX Sell
- COLL Strong Buy
- Analyst Count
- ALX 1
- COLL 4
- Target Price
- ALX $125.00
- COLL $43.75
- AVG Volume (30 Days)
- ALX 69.5K
- COLL 291.1K
- Earning Date
- ALX 08-04-2025
- COLL 08-07-2025
- Dividend Yield
- ALX 7.45%
- COLL N/A
- EPS Growth
- ALX N/A
- COLL N/A
- EPS
- ALX 7.72
- COLL 1.25
- Revenue
- ALX $219,892,000.00
- COLL $664,283,000.00
- Revenue This Year
- ALX N/A
- COLL $20.23
- Revenue Next Year
- ALX N/A
- COLL $3.82
- P/E Ratio
- ALX $31.37
- COLL $25.23
- Revenue Growth
- ALX N/A
- COLL 17.17
- 52 Week Low
- ALX $184.76
- COLL $23.23
- 52 Week High
- ALX $251.63
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- ALX 67.75
- COLL 61.58
- Support Level
- ALX $228.62
- COLL $31.53
- Resistance Level
- ALX $241.01
- COLL $32.95
- Average True Range (ATR)
- ALX 4.64
- COLL 0.88
- MACD
- ALX 1.04
- COLL 0.06
- Stochastic Oscillator
- ALX 90.25
- COLL 73.51
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.